ASH Clinical News ACN_3.12s_OCT_SUPP | Page 3
OCTOBER 2017
AMERICAN SOCIETY OF HEMATOLOGY
HEADQUARTERS
2021 L Street NW, Suite 900
Washington, DC 20036
www.hematology.org
Tel: 202-776-0544
EDITOR-IN-CHIEF
Mikkael Sekeres, MD, MS
Vice-Chair for Clinical Research
Director, Leukemia Program
Cleveland Clinic, Taussig Cancer Institute
Cleveland, OH
ASSOCIATE EDITORS
Beth Faiman, CNP, PhD
Cleveland Clinic
Cleveland, OH
Alice Ma, MD
University of North Carolina School of Medicine
Chapel Hill, NC
David Steensma, MD
CONTENTS
Dana-Farber Cancer Institute
Boston, MA
Keith Stewart, MBChB, MBA
Mayo Clinic
Scottsdale, AZ
PUBLISHER
American Medical Communications
EDITORIAL
MANAGING EDITORS
Kristin Hubing, ASH
Ariel Jones-DeMaio, AMC
ASSOCIATE MANAGING EDITOR
Kerri Fitzgerald, AMC
EDITORIAL ASSOCIATE
Laurie Adamson, ASH
ART DIRECTOR
Ari Mihos
ASSISTANT ART DIRECTOR
Charlene DePrizio
DIGITAL PROJECTS MANAGER
Chris Gedikli
ADVERTISING
NEWLY APPROVED DRUGS
The excitement over immunother-
apy for cancer treatment shows no
signs of waning, with several agents
approved by the U.S. Food and Drug
Administration this year.
2
FEATURE:
CAR T-CELL THERAPY
The approval of the first chimeric
antigen receptor T-cell therapy
represents a paradigm shift in the
treatment of cancer, but questions
remain about its rollout.
4
IN THE PIPELINE
Dozens of immunotherapeutic
agents are under investigation
for the treatment of malignant
and non-malignant hematologic
conditions.
3
FEATURE:
IMMUNOTHERAPY TRIALS
As the number of immunotherapy
clinical trials continues to grow, so
do the challenges and obstacles.
6
ACCOUNT MANAGERS
Nick Luciano
[email protected]
Gene Conselyea
[email protected]
Sima Sherman
[email protected]
Recruitment advertising orders can be sent to:
DIRECTOR, RECRUITMENT CLASSIFIEDS
Lauren Morgan
[email protected]
©2017 by the American Society of Hematology.
All materials contained in this newsletter are protected
by copyright laws and may not be used, reproduced, or
otherwise exploited in any manner without the express
prior written permission of ASH Clinical News. Any
third-party materials communicated to ASH Clinical
News become its copyrighted property and may be used,
reproduced, or otherwise exploited by ASH Clinical News.
All correspondence for the American Society of Hematology should be sent to: American Society of Hematology,
2021 L Street NW, Suite 900, Washington DC 20036.
Neither the American Society of Hematology nor the publisher is responsible for statements made by any editor or con-
tributor. Statements, editorials, or opinions expressed in ASH Clinical News magazine do not necessarily represent official
policy of the American Society of Hematology unless so stated. No responsibility is assumed by the American Society of
Hematology or the Publisher for any injury or damage to persons or property as a matter of product liability, negligence or
otherwise or from any use or operation of any methods, products, instructions or ideas contained in the material herein.
Although all advertising material published in ASH Clinical News magazine is expected to conform to ethical (med-
ical) standards, inclusion in this publication does not constitute a guarantee or endorsement by the American Society
of Hematology or the Publisher of the quality or value of such product or of the claim made of it by its manufacturer.
About the American Society of Hematology
The American Society of Hematology (ASH) is the world’s largest professional society concerned with the causes and
treatments of blood disorders. The mission of the Society is to further the understanding, diagnosis, treatment, and
prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems,
by promoting research, clinical care, education, training, and advocacy in hematology.